Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Photographed rapid HIV test results pilot novel quality assessment and training schemes.

Chiu YH, Ong J, Walker S, Kumalawati J, Gartinah T, McPhee DA, Dax EM.

PLoS One. 2011 Mar 31;6(3):e18294. doi: 10.1371/journal.pone.0018294.

2.

High viral fitness during acute HIV-1 infection.

Arnott A, Jardine D, Wilson K, Gorry PR, Merlin K, Grey P, Law MG, Dax EM, Kelleher AD, Smith DE, McPhee DA; Pulse Study Team.

PLoS One. 2010 Sep 9;5(9). pii: e12631. doi: 10.1371/journal.pone.0012631.

3.

Extremely prolonged HIV seroconversion associated with an MHC haplotype carrying disease susceptibility genes for antibody deficiency disorders.

Padiglione A, Aleksic E, French M, Arnott A, Wilson KM, Tippett E, Kaye M, Gray L, Ellett A, Crane M, Leslie DE, Lewin SR, Breschkin A, Birch C, Gorry PR, McPhee DA, Crowe SM.

Clin Immunol. 2010 Nov;137(2):199-208. doi: 10.1016/j.clim.2010.07.003. Epub 2010 Aug 8.

PMID:
20696618
4.

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee DA, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WC.

J Virol. 2009 Jul;83(14):7337-48. doi: 10.1128/JVI.00110-09. Epub 2009 May 13.

5.

Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection.

Dyer WB, Zaunders JJ, Yuan FF, Wang B, Learmont JC, Geczy AF, Saksena NK, McPhee DA, Gorry PR, Sullivan JS.

Retrovirology. 2008 Dec 11;5:112. doi: 10.1186/1742-4690-5-112.

6.

Assessing proficiency of interpretation of rapid human immunodeficiency virus assays in nonlaboratory settings: ensuring quality of testing.

Learmonth KM, McPhee DA, Jardine DK, Walker SK, Aye TT, Dax EM.

J Clin Microbiol. 2008 May;46(5):1692-7. doi: 10.1128/JCM.01761-07. Epub 2008 Mar 19.

7.

Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.

Gorry PR, McPhee DA, Verity E, Dyer WB, Wesselingh SL, Learmont J, Sullivan JS, Roche M, Zaunders JJ, Gabuzda D, Crowe SM, Mills J, Lewin SR, Brew BJ, Cunningham AL, Churchill MJ.

Retrovirology. 2007 Sep 23;4:66.

8.

Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long-term survivors infected from a single source.

Gray L, Churchill MJ, Sterjovski J, Witlox K, Learmont JC, Sullivan JS, Wesselingh SL, Gabuzda D, Cunningham AL, McPhee DA, Gorry PR.

Virol J. 2007 Jul 16;4:75.

9.

Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions.

Verity EE, Zotos D, Wilson K, Chatfield C, Lawson VA, Dwyer DE, Cunningham A, Learmont J, Dyer W, Sullivan J, Churchill M, Wesselingh SL, Gabuzda D, Gorry PR, McPhee DA.

J Virol. 2007 Sep;81(17):9268-78. Epub 2007 Jun 13.

10.

Macrophage Tropism and Cytopathicity of HIV-1 Variants Isolated Sequentially from a Long-Term Survivor Infected with nef-Deleted Virus.

Gorry PR, McPhee DA, Wesselingh SL, Churchill MJ.

Open Microbiol J. 2007;1:1-7. doi: 10.2174/1874285800701010001. Epub 2007 Jun 25.

11.
12.

Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody.

Verity EE, Williams LA, Haddad DN, Choy V, O'Loughlin C, Chatfield C, Saksena NK, Cunningham A, Gelder F, McPhee DA.

AIDS. 2006 Feb 28;20(4):505-15. Erratum in: AIDS. 2006 Apr 24;20(7):1093-4.

PMID:
16470114
13.

Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia.

Churchill M, Sterjovski J, Gray L, Cowley D, Chatfield C, Learmont J, Sullivan JS, Crowe SM, Mills J, Brew BJ, Wesselingh SL, McPhee DA, Gorry PR.

J Infect Dis. 2004 Dec 15;190(12):2181-6. Epub 2004 Nov 16.

PMID:
15551218
15.

A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals.

Pett SL, Williams LA, Day RO, Lloyd AR, Carr AD, Clezy KR, Emery S, Kaplan E, McPhee DA, McLachlan AJ, Gelder FB, Lewin SR, Liauw W, Williams KM.

HIV Clin Trials. 2004 Mar-Apr;5(2):91-8.

PMID:
15116285
16.
17.

HIV-1 Nef control of cell signalling molecules: multiple strategies to promote virus replication.

Greenway AL, Holloway G, McPhee DA, Ellis P, Cornall A, Lidman M.

J Biosci. 2003 Apr;28(3):323-35. Review.

18.

Adaptive changes after human immunodeficiency virus type 1 transmission.

Lawson VA, Oelrichs R, Guillon C, Imrie AA, Cooper DA, Deacon NJ, McPhee DA.

AIDS Res Hum Retroviruses. 2002 May 20;18(8):545-56.

PMID:
12036484
19.

Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis.

Greenway AL, McPhee DA, Allen K, Johnstone R, Holloway G, Mills J, Azad A, Sankovich S, Lambert P.

J Virol. 2002 Mar;76(6):2692-702.

20.

HIV-1 Nef: a critical factor in viral-induced pathogenesis.

Greenway AL, Holloway G, McPhee DA.

Adv Pharmacol. 2000;48:299-343. Review. No abstract available.

PMID:
10987095
21.

Rapid full-length genomic sequencing of two cytopathically heterogeneous Australian primary HIV-1 isolates.

Oelrichs RB, Lawson VA, Coates KM, Chatfield C, Deacon NJ, McPhee DA.

J Biomed Sci. 2000 Mar-Apr;7(2):128-35.

PMID:
10754387
22.

Visualisation of phenotypically mixed HIV-1 and HTLV-I virus particles by electron microscopy.

Lawson VA, Lee JY, Doultree JC, Marshall JA, McPhee DA.

J Biomed Sci. 2000 Jan-Feb;7(1):71-4.

PMID:
10644892
23.
24.

Novel endogenous type D retroviral particles expressed at high levels in a SCID mouse thymic lymphoma.

Ristevski S, Purcell DF, Marshall J, Campagna D, Nouri S, Fenton SP, McPhee DA, Kannourakis G.

J Virol. 1999 Jun;73(6):4662-9.

25.
26.

Anomalies in Nef expression within the central nervous system of HIV-1 positive individuals/AIDS patients with or without AIDS dementia complex.

McPhee DA, Greenway AL, Holloway G, Smith K, Deacon N, Pemberton L, Brew BJ.

J Neurovirol. 1998 Jun;4(3):291-300.

PMID:
9639072
27.

Serological detection of attenuated HIV-1 variants with nef gene deletions.

Greenway AL, Mills J, Rhodes D, Deacon NJ, McPhee DA.

AIDS. 1998 Apr 16;12(6):555-61.

PMID:
9583594
28.

Efficacy of fusion peptide homologs in blocking cell lysis and HIV-induced fusion.

Silburn KA, McPhee DA, Maerz AL, Poumbourios P, Whittaker RG, Kirkpatrick A, Reilly WG, Manthey MK, Curtain CC.

AIDS Res Hum Retroviruses. 1998 Mar 20;14(5):385-92.

PMID:
9546797
29.

Elimination of sequence ambiguities by a single-step modification of a solid-phase, single-stranded sequencing protocol.

Lawson VA, McPhee DA, Deacon NJ.

Biotechniques. 1996 Sep;21(3):356-8. No abstract available.

30.

Response: Attenuated HIV Vaccine: Caveats.

Deacon NJ, McPhee DA, Crowe S, Learmont J, Mills J.

Science. 1996 Mar 29;271(5257):1791-2. No abstract available.

PMID:
17812357
31.

Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients.

Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, Lawson VA, Crowe S, Maerz A, Sonza S, Learmont J, Sullivan JS, Cunningham A, Dwyer D, Dowton D, Mills J.

Science. 1995 Nov 10;270(5238):988-91.

PMID:
7481804
32.

Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure.

Poumbourios P, el Ahmar W, McPhee DA, Kemp BE.

J Virol. 1995 Feb;69(2):1209-18.

33.

Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses.

Brown LE, White DO, Agius C, Kemp BE, Yatzakis N, Poumbourios P, McPhee DA, Jackson DC.

Arch Virol. 1995;140(4):635-54.

PMID:
7540829
34.

Accumulation of unintegrated circular viral DNA in monocytes and growth-arrested T cells following infection with HIV-1.

Sonza S, Kiernan RE, Maerz AL, Deacon NJ, McPhee DA, Crowe SM.

J Leukoc Biol. 1994 Sep;56(3):289-93. Review.

PMID:
8083601
35.
36.

Synthetic peptide analogs of intercellular adhesion molecule 1 (ICAM-1) inhibit HIV-1 replication in MT-2 cells.

Fecondo JV, Pavuk NC, Silburn KA, Read DM, Mansell AS, Boyd AW, McPhee DA.

AIDS Res Hum Retroviruses. 1993 Aug;9(8):733-40.

PMID:
8105834
37.

Bacterial lipopolysaccharide mediates the loss of CD4 from the surface of purified peripheral blood monocytes.

Neate EV, Greenhalgh AM, McPhee DA, Crowe SM.

Clin Exp Immunol. 1992 Dec;90(3):539-44.

38.
39.

A new electron microscope positive staining method for viruses in suspension.

Doultree JC, Kiernan RE, Lee JY, Bowden DS, McPhee DA, Tokuyasu KT, Marshall JA.

J Virol Methods. 1992 Jun;37(3):321-35.

PMID:
1378851
40.

N-terminal residues 105-117 of HIV-1 gp120 are not involved in CD4 binding.

el Ahmar W, Poumbourios P, McPhee DA, Kemp BE.

AIDS Res Hum Retroviruses. 1991 Oct;7(10):855-8.

PMID:
1720631
41.

Antibodies to gp41 and nef in otherwise HIV-negative homosexual man with Kaposi's sarcoma.

Bowden FJ, McPhee DA, Deacon NJ, Cumming SA, Doherty RR, Sonza S, Lucas CR, Crowe SM.

Lancet. 1991 Jun 1;337(8753):1313-4.

PMID:
1674298
42.

Rapid whole blood assay for HIV-1 seropositivity using an Fab-peptide conjugate.

Wilson KM, Gerometta M, Rylatt DB, Bundesen PG, McPhee DA, Hillyard CJ, Kemp BE.

J Immunol Methods. 1991 Apr 8;138(1):111-9.

PMID:
2019740
43.

Use of a conserved immunodominant epitope of HIV surface glycoprotein gp41 in the detection of early antibodies.

Cumming SA, McPhee DA, Maskill WJ, Kemp BE, Doherty RR, Gust ID.

AIDS. 1990 Jan;4(1):83-6.

PMID:
1690552
44.

Human monoclonal antibodies to HIV-1: cross-reactions with gag and env products.

Pollock BJ, McKenzie AS, Kemp BE, McPhee DA, D'Apice AJ.

Clin Exp Immunol. 1989 Dec;78(3):323-8.

46.

Quantitation of infectious human immunodeficiency virus using a modified plaque forming assay.

Kiernan RE, McPhee DA, Doherty RR.

J Virol Methods. 1988 Dec;22(2-3):303-8.

PMID:
2464609
47.

Autologous red cell agglutination assay for HIV-1 antibodies: simplified test with whole blood.

Kemp BE, Rylatt DB, Bundesen PG, Doherty RR, McPhee DA, Stapleton D, Cottis LE, Wilson K, John MA, Khan JM, et al.

Science. 1988 Sep 9;241(4871):1352-4.

PMID:
3413497
48.

Transmission of Akabane virus from the ewe to the early fetus (32 to 53 days).

Parsonson IM, McPhee DA, Della-Porta AJ, McClure S, McCullagh P.

J Comp Pathol. 1988 Aug;99(2):215-27.

PMID:
3141487
49.

Maturation of immunological reactivity in the fetal lamb infected with Akabane virus.

McClure S, McCullagh P, Parsonson IM, McPhee DA, Della-Porta AJ, Orsini A.

J Comp Pathol. 1988 Aug;99(2):133-43.

PMID:
3141486
50.

Recognition of envelope and tat protein synthetic peptide analogs by HIV positive sera or plasma.

McPhee DA, Kemp BE, Cumming S, Stapleton D, Gust ID, Doherty RR.

FEBS Lett. 1988 Jun 20;233(2):393-6.

Supplemental Content

Loading ...
Support Center